Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02040857
Title A Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute|Pfizer
Indications

breast cancer

Her2-receptor negative breast cancer

Therapies

Exemestane

Palbociclib

Tamoxifen

Letrozole

Anastrozole

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.